Evgen Pharma Share Discussion Threads

[moneymunch] 19/5/2020 14:54

The massive trades yesterday obviously suggests that something major is going on behind the scenes, and coming a trading day after the Rns confirming they are in discussions for potential funding for Covid-19 patient trials, suggests that the trades are a positive indication at this stage imho. Gla :-)

[moneymunch] 19/5/2020 14:32

Me too Bumpa, and looks perfectly poised and primed in anticipation of news. Gl :')

[bumpa33] 19/5/2020 14:05

keeping an eye on the trades this afternoon - let’s see if yesterday afternoon was a one off.

[moneymunch] 19/5/2020 08:06

Lol Ardino, better keep eating those greens especially Broccoli and Kale, looks like sulphorphane is a panacea for a myriad of conditions, hence the potential funding of SFX-01 for Covid-19 patient trials....Gla Holders and fingers firmly crossed for Transformational funding news.:-)

[moneymunch] 19/5/2020 08:03

On and UP!!! :-)

[ardinno] 19/5/2020 07:53

Imagine if they announce a cure for COVID-19 which also reverses the effects of Alzheimer’s and completely eradicates all types of cancer - the share price here will skyrocket! Surely this is odds-on coupled with the sudden departure of the CEO and not to mention the fact that I really want the price to go up? GLA!!!!!!!!!!!!!!!!

[chuffer2] 19/5/2020 07:42

And so it begins....
Expect relentless posts

[bumpa33] 19/5/2020 07:42

moneymunch - they ain’t all buys, we’d have been north of 20p if so - lots of transfers and the kind of shareholding movements you get prior to some hopefully pretty juicy news. The mm’s were certainly scrambling for stock at the close though.

[moneymunch] 19/5/2020 07:21

The late reported incredibly massive trades yesterday, that all looked like buys imho, and hopefully are. Fingers crossed that we could have a major stake builder and a TR1 is in the pipeline. The timing of Friday's RNS essentially allows an insider to accumulate, without that Rns, any major accumulation of shares before a material event would be scrutinised and held up as insider dealing!!!??? Gla holders...Potential Transformational funding news could drop at anytime along with news of a new CEO, to replace the last one who left rather abruptly and swiftly, which could indicate that funding for SFX-01 patient trials for Covid-19 were dependent on a change of leadership??? :-)

[moneymunch] 18/5/2020 20:35

Lol chuffer, be fair mate, I jumped on MTFB on the first rise 0.15p to 0.7p plus and again at 0.31p the day it hit 1.49p, that was the day when the Rns confirmed that Lammellars Dirctor had joined the BoD. The first 4 to 5 posts on that day before opening on Advfn and on Lse were mine, which highlighted the strong connection with Lamellar, not my opinion but cut and paste of collaboration and connection which strongly suggested that Lamellar could be the RTO target, and any right minded pi would have taken profit on such a rise. EVG came to my attention when its share price rose by 100% plus on thin air, no news, and so bought in the next day on the drop after a bit of research, and have continued adding ever since, including the drop on Friday after the Rns and on today's drop, several times from profit from MTFB, ie I sold some more MTFB to buy EVG, not because I don't rate MTFB, but because I think EVG's potential Transformational news is likely to drop before MTFB's , I might be right or I might be wrong,but not long to find out imho. I'm still holding MTFB, but have commented less on the bb because of the recent performance of the sp, and my main focus is EVG at the moment, for extremely obvious reasons, following Friday's RNS, and will again be increasing my holding in MTFB if all goes to plan here. Gl :-)

Ps I'm not a P & D, MTFB still remains above 1p, and their potential hasn't changed...RT0 news is on its way. Gl ;-)

[chuffer2] 18/5/2020 19:46

Here we go, rinse and repeat.
Tell me, if you though Motifbio was going to rise soooooo considerably as you have been stating numerous times.
Why would you top slice?????
Your a pumper and dumped and l have to say, bloody good at it.
You've pulled in a lot of suckers and fair play to you as you must of made some Wonga.
No doubt you will be here posting a numerous amount of times doing the same thing before moving onto the next one.
Good luck to you.....

[moneymunch] 18/5/2020 19:30

Hi Bumpa, any more opinion on those incredibly large and numerous trades, and anyone else's opinion that Friday's Rns opened the door for a major stake builder ( insider ) to accumulate today
if indeed they were buys, they certainly looked like buys ??? Gla....not long before we find out I reckon. ;-)

[moneymunch] 18/5/2020 18:11

Lol, chuffer, I'm still holding MTFB, but have transferred a significant amount of profit to EVG, from the first significant rise where my average was initially 0.15p before it headed to 0.7p plus, and then piled in again on the Lamellar Director Rns at 0.31p which saw it close 1.49p that day, and so I'm sure the majority of pi's would have taken profit under such circumstances. I bought more MTFbB on the TR1 news my holding now is average of 0.75p, but not as many shares ( value wise ) I now have in EVG, which is currently in focus, while we await news at MTFB, and if good news comes here first, which I'm now betting on, then significant profit will be moved back into MTFB. Gl :-)

[toffeeman] 18/5/2020 17:59

Well if that volume does not presage either a decent rise or a desperate fall I shall be surprised.

[moneymunch] 18/5/2020 17:39

Massive trades Bumpa, and they all look like buys imho...and hopefully are...exciting times. Gl ;'l

[moneymunch] 18/5/2020 17:32

Fingers crossed we've got a TR1 on the way , as well as the funding Rns.Gl :')

Ps Friday's Rns essentially allows an insider to build up a stake pre funding news, otherwise anyone building a major stake without Friday's Rns would be scrutinised and held up as insider dealing before a material event??? Gl ;')

[bumpa33] 18/5/2020 17:27

Some other late big stuff gone through, will check again on those 2.8m - that’s some volume regardless though.

[bumpa33] 18/5/2020 17:06

Investec did that business, probably the one transfer of 2.86m, the others cancelled out. Whatever, the form switched from offered to no stock at all on offer just before the close.

[moneymunch] 18/5/2020 17:05

A universal remedy??? and so hopefully a panacea for Covid-19, can you imagine??? There are dozens of articles highlighting the effectiveness and attributes of Sulforaphane found in Broccoli and kale etc for a myriad of different diseases , including anti-,inflammatory properties associated with lung disorders, as witnessed in Covid-19.....Fingers crossed for a stella RNS. Gla :-)

[moneymunch] 18/5/2020 16:58

Maybe straight into phase 111 patient trials SFX-01 has successfully completed phase 11 trials for Breast cancer, and they also completed a phase 11 trial for a therapy for strokes, which was found not to effective, and so presumably SFX-01'can go straight into phase 111 patient trials for Covid-19 if funding is secured.

Here's the Drug pipeline, which is dated 7/5/20 on a Google search for SFX-01 phase 11..Gl :-)


MENU

PIPELINESFX-01: BREAST CANCER (STATUS: PHASE IIB READY)

Evgen Pharma’s clinical plans in oncology started with a Phase II trial (named STEM) in patients with ER+ metastatic breast cancer led by chief investigator Dr Sacha Howell at the Christie NHS Foundation Trust (Europe’s largest single-site cancer centre) and conducted at a number of other sites across Europe.

In March 2019, Evgen Pharma announced positive results from the open-label Phase II STEM trial of SFX-01 in 46 patients with oestrogen-positive metastatic breast cancer. The headlines were:

i) Conclusive evidence of anti-cancer activity via objective responses (tumour shrinkage)

ii) 24% of patients showed a durable clinical benefit for at least six months, despite the late stage of disease and patients’ established resistance to hormone therapy. Of these, five patients received SFX-01 for over 12 months and one patient remained on treatment for over 18 months.

iii) A mild and favourable side effect profile for an anti-cancer drug.

All STEM patients had ER+ metastatic breast cancer and had previously received treatment with either tamoxifen, aromatase inhibitors (AI) or fulvestrant. Prior to entry to the STEM trial, patients must have previously responded to their current hormone therapy for at least six months but then present with progressive disease, thereby demonstrating the start of resistance to the hormone therapy. Once entered into the trial, patients continued to receive their failing hormone therapy in addition to SFX-01 and have regular scans through to week 24. Patients discontinued the trial when one of the scans shows disease progression, or at week 24. Those patients who did not progress by week 24 were allowed to continue to receive treatment in an extension phase until disease progression.

POSTERS AND PRESENTATIONS

A poster entitled “SFX-01 targets STAT3 signalling to inhibit stem-like cells in breast cancer patient-derived xenograft tumours“, presented at the UK Interdisciplinary Breast Cancer Symposium 2018, can be viewed here.

A poster entitled “STEM: SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer“, presented at the San Antonio Breast Cancer Symposium 2018, can be viewed here.

A poster entitled “;Novel biomarkers for sulforaphane treated patients in ER+/HER- metastatic breast cancer” presented at ABPP 2019, can be viewed here.

The STEM Headline Results presentation from 25 March 2019 can be viewed here.

The STEM results as presented by poster at ESMO on 29 September 2019 can be viewed here.

SFX-01: OTHER CLINICAL PROGRAMMES (STATUS: PHASE II READY)

Evgen Pharma has announced that it has entered into MoUs to support investigator-led trials in:

i) Autism at Guy’s and St Thomas’ NHS Foundation Trust, London, UK

ii) NASH at the University of Dundee, UK

iii) Chronic Kidney Disease at Rochester University, New York

The respective investigators and their institutions are currently preparing for these trials and in the process of seeking grant funding.

SFX-01: PRECLINICAL PROGRAMMES

Evgen Pharma also supports a number of investigator-led preclinical studies on SFX-01 in other therapeutic areas. In addition, our own preclinical data relating to multiple sclerosis was presented at ECTRIMS 2016. The abstract can be accessed at this link and the associated poster at this link.

SFX SERIES

Finally, Evgen Pharma also holds the exclusive world-wide rights to a range of novel sulforaphane analogues developed by the medicinal chemistry group at the University of Seville in Spain. These compounds are in preclinical investigation.

DID YOU KNOW?

Over 3000 publications have described the efficacy of sulforaphane in various disease models and the underlying mechanisms of action. Source: Pubmed

"Sulforaphane shows a range of biological activities and health benefits in humans, has been found to be a very promising chemopreventive agent against not only a variety of cancers such as breast, prostate, colon, skin, lung, stomach, and bladder but also against cardiovascular and neurodegenerative diseases and diabetes"

[scottishfield] 18/5/2020 16:57

V good recovery, strong.

[euclid5] 18/5/2020 16:44

ok fair points, thanks - lets hope news get released in the next few days & it's a good pharma co involved - I guess they will be in Phase II trails?